APTO Overview

KPMG's Departure: Aptose Biosciences announced that KPMG LLP will not be re-appointed as its independent auditor for the 2025 annual audit, although they will continue to review quarterly financial results until mid-2025. The decision was made without the Company's consent or involvement from its Board of Directors.

Company Overview: Aptose is a clinical-stage biotechnology firm focused on developing precision oncology treatments, particularly for acute myeloid leukemia (AML), with its lead compound tuspetinib (TUS) being developed as a frontline therapy.

Aptose Biosciences Announcement: Aptose Biosciences Inc. will participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference on May 5-6, 2025, where CEO Dr. William G. Rice will present and hold one-on-one meetings with investors.

Company Focus and Product Development: Aptose is focused on developing precision oncology therapies, particularly its lead compound tuspetinib (TUS), aimed at treating newly diagnosed acute myeloid leukemia (AML) as part of a triple drug therapy regimen.

U.S. Stock Market Performance: U.S. stocks saw gains with the Nasdaq Composite up over 1%, while the Dow and S&P 500 also increased. Notable movers included bioAffinity Technologies, which surged 260%, and Microvast Holdings, which rose 24% after positive financial results.

Economic Indicators: U.S. construction spending rose by 0.7% in February, while job openings fell to 7.568 million. Manufacturing PMIs showed mixed results, with the S&P Global PMI at 50.2 and ISM PMI declining to 49.

Aptose Biosciences Delisting: Aptose Biosciences Inc. announced it will be delisting from the Nasdaq due to its inability to meet equity requirements by the March 31 deadline, resulting in a 43.4% drop in share price to $1.78.

Continued Trading on TSX: Despite the delisting from Nasdaq, Aptose's shares will continue to be traded on the Toronto Stock Exchange as the company focuses on developing a new drug therapy for acute myeloid leukemia.